-
1
-
-
0029554401
-
KRN7000, a novel immunomodulator, and its antitumor activities
-
Kobayashi E, Motoki K, Uchida T, Fukushima H, Koezuka Y. KRN7000, a novel immunomodulator, and its antitumor activities. Oncol Res 1995; 7:529-34.
-
(1995)
Oncol Res
, vol.7
, pp. 529-534
-
-
Kobayashi, E.1
Motoki, K.2
Uchida, T.3
Fukushima, H.4
Koezuka, Y.5
-
2
-
-
0029882597
-
Enhancing effects of alpha-,beta-monoglycosylceramides on natural killer cell activity
-
Kobayashi E, Motoki K, Yamaguchi Y, Uchida T, Fukushima H, Koezuka Y. Enhancing effects of alpha-,beta-monoglycosylceramides on natural killer cell activity. Bioorg Med Chem 1996; 4:615-9.
-
(1996)
Bioorg Med Chem
, vol.4
, pp. 615-619
-
-
Kobayashi, E.1
Motoki, K.2
Yamaguchi, Y.3
Uchida, T.4
Fukushima, H.5
Koezuka, Y.6
-
3
-
-
0030696696
-
CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides
-
Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Motoki K, et al. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 1997; 278:1626-9.
-
(1997)
Science
, vol.278
, pp. 1626-1629
-
-
Kawano, T.1
Cui, J.2
Koezuka, Y.3
Toura, I.4
Kaneko, Y.5
Motoki, K.6
-
4
-
-
0032547823
-
CD1d-restricted recognition of synthetic glycolipid antigens by human natural killer T-cells
-
Spada FM, Koezuka Y, Porcelli SA. CD1d-restricted recognition of synthetic glycolipid antigens by human natural killer T-cells. J Exp Med 1998; 188:1529-34.
-
(1998)
J Exp Med
, vol.188
, pp. 1529-1534
-
-
Spada, F.M.1
Koezuka, Y.2
Porcelli, S.A.3
-
5
-
-
13144249230
-
Natural killer-like non-specific tumor cell lysis mediated by specific ligand-activated Valpha14 NKT cells
-
Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Sato H, et al. Natural killer-like non-specific tumor cell lysis mediated by specific ligand-activated Valpha14 NKT cells. Proc Natl Acad Sci USA 1998; 95:5690-3.
-
(1998)
Proc Natl Acad Sci USA
, vol.95
, pp. 5690-5693
-
-
Kawano, T.1
Cui, J.2
Koezuka, Y.3
Toura, I.4
Kaneko, Y.5
Sato, H.6
-
6
-
-
0032242177
-
Antitumor activity of alpha-galactosylceramide, KRN7000, in mice with EL-4 hepatic metastasis and its cytokine production
-
Nakagawa R, Motoki K, Nakamura H, Ueno H, Iijima R, Yamauchi A, et al. Antitumor activity of alpha-galactosylceramide, KRN7000, in mice with EL-4 hepatic metastasis and its cytokine production. Oncol Res 1998; 10:561-8.
-
(1998)
Oncol Res
, vol.10
, pp. 561-568
-
-
Nakagawa, R.1
Motoki, K.2
Nakamura, H.3
Ueno, H.4
Iijima, R.5
Yamauchi, A.6
-
7
-
-
0033650499
-
Antitumor activity of alpha-galactosylceramide, KRN7000, in mice with the melanoma B16 hepatic metastasis and immunohistological study of tumor infiltrating cells
-
Nakagawa R, Serizawa I, Motoki K, Sato M, Ueno H, Iijima R, et al. Antitumor activity of alpha-galactosylceramide, KRN7000, in mice with the melanoma B16 hepatic metastasis and immunohistological study of tumor infiltrating cells. Oncol Res 2000; 12:51-8.
-
(2000)
Oncol Res
, vol.12
, pp. 51-58
-
-
Nakagawa, R.1
Serizawa, I.2
Motoki, K.3
Sato, M.4
Ueno, H.5
Iijima, R.6
-
8
-
-
0036896332
-
A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors
-
Giaccone G, Punt CJ, Ando Y, Ruijter R, Nishi N, Peters M, et al. A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res 2002; 8:3702-9.
-
(2002)
Clin Cancer Res
, vol.8
, pp. 3702-3709
-
-
Giaccone, G.1
Punt, C.J.2
Ando, Y.3
Ruijter, R.4
Nishi, N.5
Peters, M.6
-
9
-
-
20144388064
-
A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer
-
Ishikawa A, Motohashi S, Ishikawa E, Fuchida H, Higashino K, Otsuji M, et al. A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res 2005; 11:1910-7.
-
(2005)
Clin Cancer Res
, vol.11
, pp. 1910-1917
-
-
Ishikawa, A.1
Motohashi, S.2
Ishikawa, E.3
Fuchida, H.4
Higashino, K.5
Otsuji, M.6
-
10
-
-
33750709275
-
A phase I study of in vitro expanded natural killer T-cells in patients with advanced and recurrent non-small cell lung cancer
-
Motohashi S, Ishikawa A, Ishikawa E, Otsuji M, Iizasa T, Hanaoka H, et al. A phase I study of in vitro expanded natural killer T-cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res 2006; 12:6079-86.
-
(2006)
Clin Cancer Res
, vol.12
, pp. 6079-6086
-
-
Motohashi, S.1
Ishikawa, A.2
Ishikawa, E.3
Otsuji, M.4
Iizasa, T.5
Hanaoka, H.6
-
11
-
-
0028478117
-
Activation of T lymphocytes for the adoptive immunotherapy of cancer
-
Sussman JJ, Shu S, Sondak VK, Chang AE. Activation of T lymphocytes for the adoptive immunotherapy of cancer. Ann Surg Oncol 1994; 1:296-306.
-
(1994)
Ann Surg Oncol
, vol.1
, pp. 296-306
-
-
Sussman, J.J.1
Shu, S.2
Sondak, V.K.3
Chang, A.E.4
-
12
-
-
0034798589
-
T-cell adoptive therapy of tumors: Mechanisms of improved therapeutic performance
-
Cohen PA, Peng L, Kjaergaard J, Plautz GE, Finke JH, Koski GK, et al. T-cell adoptive therapy of tumors: mechanisms of improved therapeutic performance. Crit Rev Immunol 2001; 21:215-48.
-
(2001)
Crit Rev Immunol
, vol.21
, pp. 215-248
-
-
Cohen, P.A.1
Peng, L.2
Kjaergaard, J.3
Plautz, G.E.4
Finke, J.H.5
Koski, G.K.6
-
13
-
-
24644458827
-
Human natural killer cells: A comprehensive review
-
Sinkovics JG, Horvath JC. Human natural killer cells: a comprehensive review. Int J Oncol 2005; 27:5-47.
-
(2005)
Int J Oncol
, vol.27
, pp. 5-47
-
-
Sinkovics, J.G.1
Horvath, J.C.2
-
15
-
-
84944285022
-
High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity and histologic findings
-
Lotze MT, Chang AE, Seipp CA, Simpson C, Vetto JT, Rosenberg SA. High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity and histologic findings. JAMA 1986; 256:3117-24.
-
(1986)
JAMA
, vol.256
, pp. 3117-3124
-
-
Lotze, M.T.1
Chang, A.E.2
Seipp, C.A.3
Simpson, C.4
Vetto, J.T.5
Rosenberg, S.A.6
-
16
-
-
0023023119
-
Intraperitoneal administration of interleukin-2 in patients with cancer
-
Lotze MT, Custer MC, Rosenberg SA. Intraperitoneal administration of interleukin-2 in patients with cancer. Arch Surg 1986; 121:1373-9.
-
(1986)
Arch Surg
, vol.121
, pp. 1373-1379
-
-
Lotze, M.T.1
Custer, M.C.2
Rosenberg, S.A.3
-
17
-
-
0025345935
-
High-dose recombinant interleukin-2 alone: A regimen with limited activity in the treatment of advanced renal cell carcinoma
-
Abrams JS, Rayner AA, Wiernik PH, Parkinson DR, Eisenberger M, Aronson FR, et al. High-dose recombinant interleukin-2 alone: a regimen with limited activity in the treatment of advanced renal cell carcinoma. J Natl Cancer Inst 1990; 82:1202-6.
-
(1990)
J Natl Cancer Inst
, vol.82
, pp. 1202-1206
-
-
Abrams, J.S.1
Rayner, A.A.2
Wiernik, P.H.3
Parkinson, D.R.4
Eisenberger, M.5
Aronson, F.R.6
-
18
-
-
0025085675
-
Interleukin-2 therapy in patients with metastatic malignant melanoma: A phase II study
-
Parkinson DR, Abrams JS, Wiernik PH, Rayner AA, Margolin KA, Van Echo DA, et al. Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study. J Clin Oncol 1990; 8:1650-6.
-
(1990)
J Clin Oncol
, vol.8
, pp. 1650-1656
-
-
Parkinson, D.R.1
Abrams, J.S.2
Wiernik, P.H.3
Rayner, A.A.4
Margolin, K.A.5
Van Echo, D.A.6
-
19
-
-
0025000864
-
Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity
-
Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R, Gilboa E. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 1990; 172:1217-24.
-
(1990)
J Exp Med
, vol.172
, pp. 1217-1224
-
-
Gansbacher, B.1
Zier, K.2
Daniels, B.3
Cronin, K.4
Bannerji, R.5
Gilboa, E.6
-
20
-
-
0026472495
-
Retroviral gene transfer induced constitutive expression of interleukin-2 or interferon-gamma in irradiated human melanoma cells
-
Gansbacher B, Zier K, Cronin K, Hantzopoulos PA, Bouchard B, Houghton A, et al. Retroviral gene transfer induced constitutive expression of interleukin-2 or interferon-gamma in irradiated human melanoma cells. Blood 1992; 80:2817-25.
-
(1992)
Blood
, vol.80
, pp. 2817-2825
-
-
Gansbacher, B.1
Zier, K.2
Cronin, K.3
Hantzopoulos, P.A.4
Bouchard, B.5
Houghton, A.6
-
21
-
-
0027968048
-
Adoptive immunotherapy with murine tumor-specific T lymphocytes engineered to secrete interleukin 2
-
Nakamura Y, Wakimoto H, Abe J, Kanegae Y, Saito I, Aoyagi M, et al. Adoptive immunotherapy with murine tumor-specific T lymphocytes engineered to secrete interleukin 2. Cancer Res 1994; 54:5757-60.
-
(1994)
Cancer Res
, vol.54
, pp. 5757-5760
-
-
Nakamura, Y.1
Wakimoto, H.2
Abe, J.3
Kanegae, Y.4
Saito, I.5
Aoyagi, M.6
-
22
-
-
4243125420
-
Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model
-
Nakamura K, Ito Y, Kawano Y, Kurozumi K, Kobune M, Tsuda H, et al. Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther 2004; 11:1155-64.
-
(2004)
Gene Ther
, vol.11
, pp. 1155-1164
-
-
Nakamura, K.1
Ito, Y.2
Kawano, Y.3
Kurozumi, K.4
Kobune, M.5
Tsuda, H.6
-
23
-
-
34848861126
-
Intratumoral delivery of vector mediated IL-2 in combination with vaccine results in enhanced T-cell avidity and anti-tumor activity
-
Kudo-Saito C, Garnett CT, Wansley EK, Schlom J, Hodge JW. Intratumoral delivery of vector mediated IL-2 in combination with vaccine results in enhanced T-cell avidity and anti-tumor activity. Cancer Immunol Immunother 2007; 56:1897-910.
-
(2007)
Cancer Immunol Immunother
, vol.56
, pp. 1897-1910
-
-
Kudo-Saito, C.1
Garnett, C.T.2
Wansley, E.K.3
Schlom, J.4
Hodge, J.W.5
-
24
-
-
0037279047
-
Enhanced antitumor effect of RGD fiber-modified adenovirus for gene therapy of oral cancer
-
Dehari H, Ito Y, Nakamura T, Kobune M, Sasaki K, Yonekura N, et al. Enhanced antitumor effect of RGD fiber-modified adenovirus for gene therapy of oral cancer. Cancer Gene Ther 2003; 10:75-85.
-
(2003)
Cancer Gene Ther
, vol.10
, pp. 75-85
-
-
Dehari, H.1
Ito, Y.2
Nakamura, T.3
Kobune, M.4
Sasaki, K.5
Yonekura, N.6
-
25
-
-
0036327585
-
Dose of adenoviral vectors expressing interleukin-2 plays an important role in combined gene therapy with cytosine deaminase/5-fluorocytosine: Preclinical consideration
-
Nakamori M, Iwahashi M, Ueda K, Tsunoda T, Terasawa H, Hamada H, et al. Dose of adenoviral vectors expressing interleukin-2 plays an important role in combined gene therapy with cytosine deaminase/5-fluorocytosine: preclinical consideration. Jpn J Cancer Res 2002; 93:706-15.
-
(2002)
Jpn J Cancer Res
, vol.93
, pp. 706-715
-
-
Nakamori, M.1
Iwahashi, M.2
Ueda, K.3
Tsunoda, T.4
Terasawa, H.5
Hamada, H.6
-
26
-
-
0028037530
-
A simple and efficient method for purification of infectious recombinant adenovirus
-
Kanegae Y, Makimura M, Saito I. A simple and efficient method for purification of infectious recombinant adenovirus. Jpn J Med Sci Biol 1994; 47:157-66.
-
(1994)
Jpn J Med Sci Biol
, vol.47
, pp. 157-166
-
-
Kanegae, Y.1
Makimura, M.2
Saito, I.3
-
27
-
-
0035138146
-
Anti-metastatic gene therapy utilizing subcutaneous inoculation of EC-SOD gene transduced autologous fibroblast suppressed lung metastasis of Meth-A cells and 3LL cells in mice
-
Tanaka M, Kogawa K, Nakamura K, Nishihori Y, Kuribayashi K, Hagiwara S, et al. Anti-metastatic gene therapy utilizing subcutaneous inoculation of EC-SOD gene transduced autologous fibroblast suppressed lung metastasis of Meth-A cells and 3LL cells in mice. Gene Ther 2001; 8:149-56.
-
(2001)
Gene Ther
, vol.8
, pp. 149-156
-
-
Tanaka, M.1
Kogawa, K.2
Nakamura, K.3
Nishihori, Y.4
Kuribayashi, K.5
Hagiwara, S.6
-
28
-
-
0141958207
-
Glycolipid antigen drives rapid expansion and sustained cytokine production by NK T-cells
-
Crowe NY, Uldrich AP, Kyparissoudis K, Hammond KJ, Hayakawa Y, Sidobre S, et al. Glycolipid antigen drives rapid expansion and sustained cytokine production by NK T-cells. J Immunol 2003; 171:4020-7.
-
(2003)
J Immunol
, vol.171
, pp. 4020-4027
-
-
Crowe, N.Y.1
Uldrich, A.P.2
Kyparissoudis, K.3
Hammond, K.J.4
Hayakawa, Y.5
Sidobre, S.6
-
29
-
-
0032698211
-
Antitumor cytotoxicity mediated by ligand-activated human V alpha24 NKT cells
-
Kawano T, Nakayama T, Kamada N, Kaneko Y, Harada M, Ogura N, et al. Antitumor cytotoxicity mediated by ligand-activated human V alpha24 NKT cells. Cancer Res 1999; 59:5102-5.
-
(1999)
Cancer Res
, vol.59
, pp. 5102-5105
-
-
Kawano, T.1
Nakayama, T.2
Kamada, N.3
Kaneko, Y.4
Harada, M.5
Ogura, N.6
-
30
-
-
0033198183
-
Cutting edge: Activation of NK T-cells by CD1d and alpha-galactosylceramide directs conventional T-cells to the acquisition of a Th2 phenotype
-
Singh N, Hong S, Scherer DC, Serizawa I, Burdin N, Kronenberg M, et al. Cutting edge: activation of NK T-cells by CD1d and alpha-galactosylceramide directs conventional T-cells to the acquisition of a Th2 phenotype. J Immunol 1999; 163:2373-7.
-
(1999)
J Immunol
, vol.163
, pp. 2373-2377
-
-
Singh, N.1
Hong, S.2
Scherer, D.C.3
Serizawa, I.4
Burdin, N.5
Kronenberg, M.6
-
31
-
-
3042760542
-
Regulation of immune responses by CD1d-restricted natural killer T-cells
-
Van Kaer L. Regulation of immune responses by CD1d-restricted natural killer T-cells. Immunol Res 2004; 30:139-53.
-
(2004)
Immunol Res
, vol.30
, pp. 139-153
-
-
Van Kaer, L.1
-
33
-
-
0035424975
-
CD1-specific T-cells in microbial immunity
-
Gumperz JE, Brenner MB. CD1-specific T-cells in microbial immunity. Curr Opin Immunol 2001; 13:471-8.
-
(2001)
Curr Opin Immunol
, vol.13
, pp. 471-478
-
-
Gumperz, J.E.1
Brenner, M.B.2
-
34
-
-
0036533337
-
NKT cells - conductors of tumor immunity?
-
Smyth MJ, Crowe NY, Hayakawa Y, Takeda K, Yagita H, Godfrey DI. NKT cells - conductors of tumor immunity? Curr Opin Immunol 2002; 14:165-71.
-
(2002)
Curr Opin Immunol
, vol.14
, pp. 165-171
-
-
Smyth, M.J.1
Crowe, N.Y.2
Hayakawa, Y.3
Takeda, K.4
Yagita, H.5
Godfrey, D.I.6
-
35
-
-
0032521202
-
Treatment of hepatic metastasis of the colon26 adenocarcinoma with an alpha-galactosylceramide, KRN7000
-
Nakagawa R, Motoki K, Ueno H, Iijima R, Nakamura H, Kobayashi E, et al. Treatment of hepatic metastasis of the colon26 adenocarcinoma with an alpha-galactosylceramide, KRN7000. Cancer Res 1998; 58:1202-7.
-
(1998)
Cancer Res
, vol.58
, pp. 1202-1207
-
-
Nakagawa, R.1
Motoki, K.2
Ueno, H.3
Iijima, R.4
Nakamura, H.5
Kobayashi, E.6
-
36
-
-
0035911242
-
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis
-
Smyth MJ, Cretney E, Takeda K, Wiltrout RH, Sedger LM, Kayagaki N, et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis. J Exp Med 2001; 193:661-70.
-
(2001)
J Exp Med
, vol.193
, pp. 661-670
-
-
Smyth, M.J.1
Cretney, E.2
Takeda, K.3
Wiltrout, R.H.4
Sedger, L.M.5
Kayagaki, N.6
-
37
-
-
0033025582
-
A novel recognition motif of human NKT antigen receptor for a glycolipid ligand
-
Kawano T, Tanaka Y, Shimizu E, Kaneko Y, Kamata N, Sato H, et al. A novel recognition motif of human NKT antigen receptor for a glycolipid ligand. Int Immunol 1999; 11:881-7.
-
(1999)
Int Immunol
, vol.11
, pp. 881-887
-
-
Kawano, T.1
Tanaka, Y.2
Shimizu, E.3
Kaneko, Y.4
Kamata, N.5
Sato, H.6
-
38
-
-
0033567099
-
Expression and function of TNF-related apoptosis-inducing ligand on murine activated NK cells
-
Kayagaki N, Yamaguchi N, Nakayama M, Takeda K, Akiba H, Tsutsui H, et al. Expression and function of TNF-related apoptosis-inducing ligand on murine activated NK cells. J Immunol 1999; 163:1906-13.
-
(1999)
J Immunol
, vol.163
, pp. 1906-1913
-
-
Kayagaki, N.1
Yamaguchi, N.2
Nakayama, M.3
Takeda, K.4
Akiba, H.5
Tsutsui, H.6
-
39
-
-
0037148518
-
Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development
-
Takeda K, Smyth MJ, Cretney E, Hayakawa Y, Kayagaki N, Yagita H, et al. Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J Exp Med 2002; 195:161-9.
-
(2002)
J Exp Med
, vol.195
, pp. 161-169
-
-
Takeda, K.1
Smyth, M.J.2
Cretney, E.3
Hayakawa, Y.4
Kayagaki, N.5
Yagita, H.6
-
40
-
-
4944243249
-
+ T-cells express both TNF-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors but are resistant to TRAIL-mediated cytotoxicity
-
+ T-cells express both TNF-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors but are resistant to TRAIL-mediated cytotoxicity. Blood 2004; 104:2418-24.
-
(2004)
Blood
, vol.104
, pp. 2418-2424
-
-
Mirandola, P.1
Ponti, C.2
Gobbi, G.3
Sponzilli, I.4
Vaccarezza, M.5
Cocco, L.6
-
41
-
-
0036467427
-
Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice
-
Cretney E, Takeda K, Yagita H, Glaccum M, Peschon JJ, Smyth MJ. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol 2002; 168:1356-61.
-
(2002)
J Immunol
, vol.168
, pp. 1356-1361
-
-
Cretney, E.1
Takeda, K.2
Yagita, H.3
Glaccum, M.4
Peschon, J.J.5
Smyth, M.J.6
-
42
-
-
0942276861
-
+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity
-
+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood 2004; 103:383-9.
-
(2004)
Blood
, vol.103
, pp. 383-389
-
-
Nieda, M.1
Okai, M.2
Tazbirkova, A.3
Lin, H.4
Yamaura, A.5
Ide, K.6
-
43
-
-
9144234147
-
TRAIL and its receptors as targets for cancer therapy
-
Yagita H, Takeda K, Hayakawa Y, Smyth MJ, Okumura K. TRAIL and its receptors as targets for cancer therapy. Cancer Sci 2004; 95:777-83.
-
(2004)
Cancer Sci
, vol.95
, pp. 777-783
-
-
Yagita, H.1
Takeda, K.2
Hayakawa, Y.3
Smyth, M.J.4
Okumura, K.5
|